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trends in cardiovascular risk factors 
in diabetic patients in comparison 
to general population in iran: 
findings from National Surveys 
2007–2016
Hamid Malekzadeh1, Mojtaba Lotfaliany1,2, Afshin ostovar3, farzad Hadaegh1, 
fereidoun Azizi4, Moein Yoosefi5, farshad farzadfar5 & Davood Khalili1,2*
to determine levels of change in risk factors for cardiovascular disease among people with and without 
a previous diagnosis of diabetes from 2007 to 2016 in Iran. Data were obtained from five rounds of 
the World Health Organization STEPwise approach to Surveillance (STEPS) cross-sectional surveys. 
Participants were 7665 and 93,733 adults with and without known diabetes, respectively, aged 
25–65 years. We used logistic and linear regressions to assess the trends of risk factors. Individuals 
with known diabetes compared to those without the condition, experienced greater reductions in 
mean levels of systolic blood pressure (3.0 vs. 0.5 mmHg among women and 3.9 vs. 1.6 mmHg among 
men), diastolic blood pressure (6.4 vs. 5.11 mmHg in women and 3.3 vs. 1.8 mmHg in men), and non-
HDL cholesterol (42.4 vs. 27.2 mg/dL among women and 30.3 vs. 21.0 mg/dL among men) throughout 
these years. Men with diabetes also showed a greater reduction in the prevalence of daily cigarette 
smoking compared to their non-diabetic counterparts (7.3% vs. 2.3%). Fasting plasma glucose 
decreased among subjects with diabetes but increased among those without diabetes. Significant 
increases were observed in proportions who met goals for blood pressure, triglycerides, non-HDL 
cholesterol and LDL cholesterol in both groups; however, almost half of diabetic subjects did not 
achieve risk factor goals in 2016. Secondary prevention in diabetic patients was more effective than 
primary prevention in the general population; however, the rate of diabetic patients who met the 
designated goals for each risk factor was still suboptimal.
Diabetes is associated with premature mortality from different causes, including cardiovascular diseases (CVD)1. 
Previous studies have demonstrated the vitality of CVD risk factor control to decrease the fast-rising trend of 
this mortality and CVD events in people with  diabetes2–4. Furthermore, evidence suggests that the use of more 
intensive targets for blood pressure and cholesterol in individuals with diabetes results in a more significant 
reduction in the incidence of CVD  events5–7. However, several studies report that people with diabetes are less 
likely to achieve target goals for control of CVD risk factors than those without  diabetes8,9.
Nationally representative data that investigate trends in CVD risk factors in both the general population and 
people with diabetes in Middle Eastern countries such as Iran are scarce. Moreover, due to the lack of proper 
investigations that compare secular trends for CVD risk factors in individuals with and without diabetes in 
open
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this region, it is difficult to illustrate the impact of preventative programs on this population and also prioritize 
strategies for primary and secondary preventions.
The primary goal of this analysis is to characterize and compare the trends of body mass index (BMI), waist 
circumference (WC), blood pressure, smoking, plasma glucose and lipid measures among adults with known 
diabetes (as indicators of secondary prevention impacts) and those without known diabetes (as indicators of 
primary prevention impacts) in a nationally representative study from 2007 through 2016.
Results
Age and sex distribution of participants with and without known diabetes are presented in Table 1. The propor-
tion of women was higher among those with known diabetes. The mean age for participants was approximately 
44 years in all study years; however, for those with known diabetes, the mean age was almost ten years higher.
Trends of risk factors in persons with known diabetes. Among those with diabetes, there were sig-
nificant reductions of mean SBP (from 134 to 131 mmHg in women and 134 to 130 mmHg in men), DBP (from 
86 to 79 mmHg in women and 84 to 81 mmHg in men), LDL cholesterol (from 132 to 99 mg/dL in women and 
121 to 97 mg/dL in men), non-HDL cholesterol (from 168 to 126 mg/dL in women and 155 to 125 mg/dL in 
men) and triglycerides (from 177 to 127 mg/dL in women and 171 to 146 mg/dL in men) in both sexes. Further-
more, there were significant reductions in FPG among women (from 147 to 139 mg/dL) and HDL cholesterol 
among men (from 40 to 35 mg/dL) (Figs. 1 and 2). There was not enough evidence supporting a significant trend 
for BMI and waist circumference. 
Table 2 shows the trends of meeting goals/optimum levels of risk factors among persons with and without 
known diabetes. In both sexes, there were significant increases in the proportion of participants with an optimum 
level of blood pressure (from 47 to 58% in women and 55 to 62% in men), LDL cholesterol (from 21 to 54% in 
women and 26 to 57% in men), non-HDL cholesterol (from 21 to 58% in women and 26 to 59% in men), and 
triglycerides (from 36 to 66% in women and 39 to 53% in men). Glycemic control improved in diabetic women 
(from 49 to 55%) (Table 2) but not in diabetic men. Nevertheless, the prevalence of subjects who met HDL cho-
lesterol goal significantly reduced in both sexes (from 19 to 17% in women and 44 to 23% in men).
Trends of risk factors among persons without known diabetes. There were a significant reduction 
in mean levels of lipid profiles, specially non-HDL cholesterol (from 146 to 119 mg/dL in women and 113 to 97 
in men, 2007 vs. 2016) and triglycerides (from 132 to 100 mg/dL in women and 143 to 118 mg/dL in men) and 
prevalence of smoking (especially in men from 29.1 in 2007 to 21.8% in 2016) in both sexes. Regarding blood 
pressure, declining trends for mean DBP in both sexes and mean SBP in men were observed (Fig. 1). However, 
there was a slight, but statistically significant, increase in FPG (from 89 to 91 mg/dL in women and from 90 to 
92 mg/dL in men, 2007 vs. 2016) and waist circumference (from 88.0 to 88.8 cm in women and from 88.7 to 91.0 
in men). Only men had a significant increase in BMI (from 25.2 to 25.9 kg/m2) (Fig. 1).
In terms of optimal level of risk factors, we showed a significant increase in the proportion of those who 
had an optimal level of blood pressure (from 74.6 to 84.1% in women and 76.7 to 83.6% in men, 2007 vs. 2016), 
LDL cholesterol (from 69.1 to 91.8% in women and 74.3 to 92.4% in men), non-HDL cholesterol (from 67.6 to 
91.5% in women and 71.0 to 90.7% in men), and triglycerides (from 67.6 to 83.4% in women and 59.6 to 74.0% 
in men) in both sexes. There were also decreasing trends in meeting optimal levels of FPG (from 84.6 to 80.9 
in women and 83.7 to 78.0% in men) and HDL cholesterol (from 24.4 to 23.1% in women and 46.8 to 32.2% in 
men, 2007 vs. 2016) (Table 2).
Difference in the trend of risk factors in persons with and without known diabetes. In both 
sexes, diabetic individuals showed a greater reduction of mean SBP (3.0 vs. 0.5 mmHg in women and 3.9 vs. 
1.6 mmHg in men), DBP (6.4 vs. 5.11 mmHg in women and 3.3 vs. 1.8 mmHg in men), LDL cholesterol (32.4 
Table 1.  Age and sex distribution of the participants with and without diagnosed diabetes in five STEPS 
surveys from 2007 to 2016.
STEPS-2007 STEPS-2008 STEPS-2009 STEPS-2011 STEPS-2016
N 23,487 23,290 23,334 7551 23,738
Age, years 44.3 ± 11.4 44.2 ± 11.4 44.7 ± 11.5 44.4 ± 12.4 42.3 ± 11.1
Female, n (%) 11,683 (49.7) 11,539 (49.5) 11,545 (49.5) 4482 (59.4) 12,437 (52.4)
Known diabetes
N, (%) 1608 (6.8) 1629 (7) 1571 (6.7) 787 (10.4) 2072 (8.7)
Age, years 52 ± 8.8 52.2 ± 8.6 52.8 ± 8.7 53.3 ± 9 50.7 ± 9.9
Female, n (%) 968 (60.2) 995 (61.1) 1003 (63.8) 518 (65.8) 1278 (61.7)
No known diabetes
N, (%) 21,879 (93.2) 21,661 (93) 21,763 (93.3) 6764 (89.6) 21,666 (91.3)
Age, years 43.7 ± 11.3 43.7 ± 11.4 44.1 ± 11.4 43.4 ± 12.4 41.5 ± 10.9
Female, n (%) 10,715 (49) 10,544 (48.7) 10,542 (48.4) 3964 (58.6) 11,159 (51.5)
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vs. 21.1 mg/dL in women and 24.0 vs. 16.4 mg/dL in men), and non-HDL cholesterol (42.4 vs. 27.2 mg/dL in 
women and 30.3 vs. 21.0 mg/dL in men) compared to non-diabetics throughout 2007 to 2016 (Fig. 1).
Moreover, women without known diabetes showed an increase in FPG while there was a significant reduction 
among their counterparts. Waist circumference increased among men without known diabetes, while it remained 
unchanged among those with known diabetes (Fig. 1). Regarding meeting risk factor goals, women with diabe-





















































































































































































Figure 1.  Trends of CVD risk factor levels among women with (red dotted line) and without diabetes (black 
dashed line) through 2007–2016. Changes in mean levels Body Mass Index (BMI), Waist Circumference (WC), 
Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Daily cigarette smoking are preented for 
five STEPS surveys in 2007, 2008, 2009, 2011 and 2016. Changes in Fasting Plasma Glucose FPG), Triglycerides 
(TGs), HDL cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C) and LDL cholesterol throughout are 
presented for three STEPS surveys in 2007, 2011 and 2016.
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women (29.4 vs. 15.8). Additionally, compared to non-diabetic men, those with diabetes had significantly more 


















































































































































































Figure 2.  Trends of CVD risk factor levels among men with (red dotted line) and without diabetes (black 
dashed line) through 2007–2016. Changes in mean levels Body Mass Index (BMI), Waist Circumference (WC), 
Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Daily cigarette smoking are preented for 
five STEPS surveys in 2007, 2008, 2009, 2011 and 2016. Changes in Fasting Plasma Glucose FPG), Triglycerides 
(TGs), HDL cholesterol (HDL-C), non-HDL cholesterol (non-HDL-C) and LDL cholesterol throughout are 
presented for three STEPS surveys in 2007, 2011 and 2016.
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Discussion
In this study, we assessed national trends of cardio-metabolic risk factors from 2007 to 2016 in Iran concerning 
diabetes status. We provided some evidence on the effects of national efforts for primary and secondary preven-
tion of cardio-metabolic disorders in a Middle Eastern country. There were significant improvements in blood 
pressure levels, non-HDL lipids, and daily smoking in the Iranian population; however, a deterioration in levels 
of HDL cholesterol was observed among those with and without diabetes. Importantly, we found increasing 
levels of obesity measurements and FPG in those without diabetes. Our findings suggest that secondary preven-
tion has been more successful than primary prevention in reducing risk factors as they showed that changes in 
blood pressure, non-HDL cholesterol, FPG, and obesity (only in men) were more favorable in those with diabetes 
than those without the condition. Despite improvements over the past decade, meeting CVD risk factor goals, 
particularly among those with diabetes, remained suboptimal as almost half of Iranians with diabetes did not 
achieve risk factor goals.
Our findings regarding improvements in blood pressure and non-HDL lipid levels are in line with those of 
previous studies on Iranian populations, showing similar decreasing  trends10–12 Notably, in this study, we had 
a higher proportion of participants, with and without diabetes who met goals of blood pressure and non-HDL 
lipids (53%-92%) compared with previous studies conducted in Iran (36%-87%)10–12. Our findings are also in 
line with those of the Global Burden of Disease (GBD) and NCD Risk Factor Collaboration (NCD-RisC), which 
showed reductions in the burden of high blood pressure and dyslipidemia in the Middle East and  Worldwide13–15. 
Investigations from other countries have shown similar trends. Declines in mean SBP, DBP, LDL, non-HDL cho-
lesterol and rate of smoking with more significant decreases among individuals with diabetes have been reported 
in studies from the National Health And Nutrition Examination Survey (NHANES) and the Framingham Heart 
Study in the  US16,17 and the Health Survey for England 18. Accordingly, the prevalence of meeting blood pressure 
and LDL goals has been improved in the  US16,17. Decreasing trends in high blood pressure were also found in 
Table 2.  Age-adjusted percentages of subjects with and without diagnosed diabetes who reached goals/
optimum levels of blood pressure, fasting plasma glucose and lipid measures. *Known diabetes mellitus.
STEPS-2007 STEPS-2011 STEPS-2016
P-trend P-interactionn % (SE) n % (SE) n % (SE)
Women
Blood pressure < 140/90 mmHg
KDM* 403 47.0 (1.9) 211 44.8 (2.7) 661 57.9 (1.6)  < 0.001
0.555
Non-KDM 7424 74.6 (0.5) 2881 78.2 (0.7) 8867 84.1 (0.4)  < 0.001
Fasting plasma glu-
cose < 130 mg/dL KDM 459 49.2 (1.8) 191 37.5 (2.4) 677 54.7 (1.5)  < 0.001
0.12
Fasting plasma glu-
cose < 100 mg/dL Non-KDM 8665 84.6 (0.4) 2934 76.9 (0.7) 8036 80.9 (0.4)  < 0.001
HDL cholesterol > 50 mg/dL
KDM 200 19.4 (1.4) 136 24.7 (2.1) 218 16.8 (1.1) 0.032
0.532
Non-KDM 2652 24.4 (0.5) 1297 31.4 (0.8) 2649 23.1 (0.4) 0.004
Non-HDL cholesterol < 130 mg/
dL KDM 203 21.4 (1.5) 153 30.4 (2.3) 715 58.1 (1.5)  < 0.001
0.724
Non-HDL cholesterol < 160 mg/
dL Non-KDM 6890 67.6 (0.5) 2997 78.6 (0.7) 10,003 91.5 (0.3)  < 0.001
LDL cholesterol < 100 mg/dL KDM 205 21.2 (1.5) 153 29.3 (2.2) 678 54.5 (1.5)  < 0.001
0.798
LDL cholesterol < 130 mg/dL Non-KDM 7057 69.1 (0.5) 3081 80.7 (.7) 10,048 91.8 (.3)  < 0.001
Triglycerides < 150 mg/dL
KDM 349 36.3 (1.7) 179 35.9 (2.4) 807 65.7 (1.4)  < 0.001
0.011
Non-KDM 7038 67.6 (0.5) 2682 70.1 (0.8) 9142 83.4 (0.4)  < 0.001
Men
Blood pressure < 140/90 mmHg
KDM 321 54.7 (2.4) 122 50.74 (3.6) 452 61.5 (2.0) 0.007
0.019
Non-KDM 8138 76.7 (0.5) 2085 79.5 (0.9) 2338 83.6 (0.4)  < 0.001
Fasting plasma glu-
cose < 130 mg/dL KDM 314 50.6 (2.2) 106 40.6 (3.4) 377 47.6 (2.0) 0.554
0.003
Fasting plasma glu-
cose < 100 mg/dL Non-KDM 9233 83.7 (0.4) 1952 74.3 (0.9) 8103 78.0 (0.4)  < 0.001
HDL cholesterol > 40 mg/dL
KDM 290 43.6 (2.2) 116 38.8 (3.3) 199 23.2 (1.6)  < 0.001
0.189
Non-KDM 5490 46.8 (0.5) 1557 54.6 (1.1) 3537 32.2 (0.5)  < 0.001
Non-HDL cholesterol < 130 mg/
dL KDM 157 25.6 (2.0) 77 27.9 (3.0) 472 59.2 (2.0)  < 0.001
0.666
Non-HDL cholesterol < 160 mg/
dL Non-KDM 7768 71.0 (0.5) 2220 81.1 (0.8) 9429 90.7 (0.3)  < 0.001
LDL cholesterol < 100 mg/dL KDM 156 26.0 (2.0) 76 27.8 (3.0) 456 57.5 (2.0)  < 0.001
0.853
LDL cholesterol < 130 mg/dL Non-KDM 8123 74.3 (0.5) 2319 84.5 (0.7) 9611 92.4 (0.3)  < 0.001
Triglycerides < 150 mg/dL
KDM 244 38.7 (2.2) 91 32.0 (3.1) 428 53.4 (2.0) 0.015
0.966
Non-KDM 6712 59.6 (0.5) 1764 63.2 (1.0) 7726 74.0 (0.5)  < 0.001
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studies from France and Japan, while the prevalence of hypercholesterolemia  increased19,20. The results regarding 
HDL-cholesterol and triglycerides are different, from decreasing to no change or  increasing21,22. Regarding the 
management of diabetes, in line with our findings, a study across 28 low-middle income countries uncovered 
poor control of diabetes, indicating a significant unmet need for diabetes care in these  countries23. However, our 
results show that around 40–50% of our diabetic men and women reached the goal for glucose control, defined as 
FPG < 130, versus 23% on average in these 28 low-middle income countries, with a definition of FPG < 180 mg/
dl; indicating much better situation of glucose control in Iran.
As one of the first countries from the Eastern Mediterranean Regional Office of WHO, Iran has responded to 
"a call for action" for the prevention and control of diabetes mellitus; and the national program was designed in 
1996. The aim of this program is primary, secondary, and tertiary prevention, through community and high-risk 
screening, and the integration of diabetes care into the primary healthcare network. After the implementation 
in 2016 of IraPEN, an adaptation of WHO’s Package of essential NCD (PEN) interventions for primary health 
care, this program integrated into the guidelines for prevention and control of major NCDs in the primary health 
care system. The current study shows that secondary prevention in diabetic patients has been more effective 
than primary prevention in the general population for controlling CVD risk factors, i.e., risk factors decreased 
more in diabetic patients than in non-diabetic subjects in the general population. However, the rate of diabetic 
patients who met the designated goals for each risk factor was still suboptimal.
The favorable changes may be rooted in nutritional habits, physical activity levels, smoking, and anti-hyper-
tension or lipid-lowering drug consumption, all of which are known to be important determinants of blood 
pressure and serum lipid  levels10,11. Previous studies showed that Iranian families had reduced the consump-
tion of hydrogenated  oil24,25 and  salt26, which could explain the favorable blood pressure and lipid trends in 
Iranians. Further, previous studies showed increasing use of anti-hypertension or lipid-lowering drugs among 
 Iranian10–12. Nevertheless, the decreasing trends in blood pressure and lipid levels in our population could 
hardly be explained by an increase in physical activity, since it was shown that low physical activity is common 
in Iranian  community27,28.
Notably, by showing a significant reduction in the prevalence of daily smoking among those without known 
diabetes, this study suggests that efforts for lowering the prevalence of smoking have been successful in control-
ling the increasing  trends10. The decrease in the prevalence of daily smoking in this group might also contribute 
to the decline in non-HDL lipid and blood pressure given the substantial evidence on the positive correlation of 
smoking with high blood pressure and  dyslipidemia29,30.
On the contrary, we showed a rise in levels of obesity measurements in individuals without known diabetes 
(WC in both genders and BMI in men), which is probably the main reason for the increasing fasting plasma 
glucose trends in this  group31,32. Contrary to the results of the previous studies that showed growing trends for 
HDL cholesterol in Iranian  population10, this study showed a significant reduction in HDL cholesterol in those 
with and without diabetes. As shown in previous studies, decreasing levels of HDL cholesterol are mostly due 
to poor dietary habits and low levels of physical  activity33,34. Deterioration in obesity measurements and HDL 
cholesterol levels should raise the alarm for policymakers as it indicates efforts for improvement of dietary habits 
and physical activity came short in this Iranian population. Based on previous studies in  Iran28,35–38, the most 
important barriers to healthy nutrition and physical activity were interpersonal/cultural effects, lack of access 
to healthy foods, food preferences, media advertisements, nutrition transition, lack of time, motivation and 
prioritizing other activities over sports and high costs of the facilities. Therefore, feasible and effective national 
intervention programs are needed to curb current obesity epidemics by overcoming the barriers to healthy 
nutrition and physical activity. Despite the promising findings of several community-wide lifestyle interven-
tion programs in Iran, such as Tehran Lipid and Glucose  Study39 and Isfahan Healthy Heart  Program40, these 
programs did not scale up in national levels.
In accordance with the evidence showing a correlation between diabetes and other cardio-metabolic risk 
factors, we showed risk factor levels were higher in those with diabetes compared to those without  it10,31. Our 
findings support that the efforts on controlling blood pressure, dyslipidemia and obesity had more impacts among 
people with diabetes rather than non-diabetics. First of all, this is because diabetic patients experienced more 
reduction in mean SBP, DBP and non-HDL lipids. In addition, their obesity and blood glucose measurements 
remained steady, while people without diabetes showed a significant increase in obesity measurements. Favorable 
trends in dyslipidemia, obesity and blood glucose control in known diabetics may be due to improvements in 
care, knowledge and attitude towards diabetes as well as better adherence to lifestyle and pharmaceutical inter-
ventions. Previous studies show advancements in the quality of diabetes care, affordability of medications, and 
screening for undiagnosed diabetes as well as increasing trends in consumption of glucose-lowering (twofold in 
men and 1.5-fold in women) and lipid-lowering drugs (fourfold in men and 2.5-fold in women) among those 
with known  diabetes10,41. Educational interventions in Iran, such as Self-Management Education (PDSME) 
program, also proved to be effective in improving the knowledge and practice of  diabetes42,43, which is highly 
correlated with control of related risk  factors44.
Nevertheless, in this study, the prevalence of daily smoking remained steady in participants with diabetes, 
while its prevalence reduced significantly in those without the disease. These findings are in contrast with those 
of a previous study that showed an increasing trend for smoking in those with diabetes was significantly higher 
than increases in smoking prevalence in those without  diabetes10. This discrepancy may indicate favorable and 
radical changes in the prevalence of smoking. Another explanation may be the differences in the study sample 
and definition of smoking in this study compared to the previous studies, which were mostly cohort studies with 
local study samples and various definitions of  smoking10,11. Further research is needed to provide more robust 
evidence on trends for smoking prevalence in Iran.
Since, during the last decades, the highest number of STEPS surveys in the Middle East have been conducted 
in Iran, it was made possible to investigate the secular trend of CVD risk factors using national data for the first 
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time in this  region45. Standardized measurement methods throughout the study period were used and large 
sample sizes and multiple measurements led to high precision in estimating the prevalence and trends of differ-
ent risk factors. However, there are some limitations. We only assessed these trends for 10 years. Although the 
sampling methods were representative of the Iranian population, there were some minor differences that were 
addressed using post-stratification weighting based on age, sex, region and province categories of population in 
2011 as a reference for all years. Finally, the biochemical measurements were only available for three STEPs cycles.
conclusion
Non-HDL lipids and blood pressure levels in the Iranian population improved significantly in those with and 
without diabetes. Moreover, obesity measurements and fasting plasma glucose worsened in diabetic persons. 
This study showed favorable changes in blood pressure, non-HDL cholesterol, blood glucose, and obesity (only in 
men) were more prominent in people with diabetes compared to those without known diabetes. This indicating 
secondary prevention efforts have been more effective than primary prevention in Iran.
Methods
This study is conducted on the data documented from five STEPwise approaches to Surveillance (STEPS) surveys 
(2007, 2008, 2009, 2011, and 2016). The first STEPS in 2005 was not included due to the inconsistency of some 
measurement methods. STEPS is a standardized survey designed to help the World Health Organization (WHO) 
member states collect and disseminate consistent data about non-communicable diseases (NCD) and enable 
comparisons over time. A brief explanation of the samplings of the surveys is presented as follows.
All methods in the current study were carried out following relevant guidelines and regulations, the Center 
for Disease Control, Ministry of Health and Medical Education in Iran approved all experimental protocols, and 
all participants gave informed consent.
Study population. Using random cluster sampling methods based on instructions of WHO for  STEPS45 
23,487, 23,290, 23,334, 7551, and 23,738 adults, aged 25–65, were selected in 2007, 2008, 2009, 2011 and 2016, 
respectively. Despite differences in design and sampling methods, all surveys represented the Iranian popula-
tion. Socio-demographic information and physical measurements were collected in all five surveys, whereas 
biochemical measurements were collected only in 2007, 2011 and 2016.
The sampling method in 2007, 2008 and 2009 was similar. The sampling was conducted at levels of towns, vil-
lages and districts of large cities using a randomized cluster sampling scheme. In each province, 1000 individuals 
were selected in 50 clusters. Each cluster included 20 individuals, 10 women and 10 men, living in neighboring 
households.
The 2011 survey used a multistage cluster random sampling scheme. At the first stage, distinct counties or 
a group of adjacent counties were listed as the primary sampling units (PSU). Fifty PSUs were then picked by 
applying probability proportionate to size (PPS) random sampling. Within each PSU, urban and rural areas 
were listed as possible secondary sampling units (SSU) from which twelve SSUs were picked by employing the 
PPS method similar to the previous step. In the third stage, a list of households in each SSU referenced by their 
10-digit postal codes was developed, of which twenty postal addresses were selected randomly. At the final stage, 
one individual was selected from each selected household using Kish tables provided by WHO, and they were 
interviewed at their houses.
In 2016, a systematic cluster random sampling scheme was designed to select 31,050 individuals in 3105 
clusters (10 subjects from each cluster) from urban and rural areas of all provinces. To estimate the minimum 
sample size at the province level, calculations were based on the province with the lowest population density. 
The sample size in other provinces was determined according to their population ratio to that province. To 
control non–response errors and mind the effect of sampling design, 10% was added to the estimated sample 
size of each province. Also, to minimize costs, in more crowded provinces (those with more than 800 clusters), 
half of the estimated sample size was considered, but the applied weight in the subsequent analysis was doubled.
Medical history, clinical examination and laboratory measurements. Standard questionnaires 
based on the WHO STEPS were used to collect demographic information as well as the past medical history of 
diabetes, medication use and cigarette smoking. Blood pressure was measured three times at five-minute inter-
vals. The average of second and third readings was considered as the participants’ blood pressure.
All biochemical measurements were assessed in venous samples drawn after 12–14 h overnight fasting accord-
ing to a standard protocol and sent to collaborating centers. In 2007 and 2011, Fasting Plasma Glucose (FPG) 
was measured with enzymatic colorimetric methods with a glucose oxidase test and serum lipids, including total 
cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were determined by enzymatic methods 
(Pars Azmun, Karaj, Iran). In 2016, venous samples were transferred to the Central Reference Laboratory in 
Tehran and all laboratory tests were measured using the auto analyzer (Cobas C311 Hitachi High–Technologies 
Corporation) approved by Reference Laboratory. Low-density lipoprotein (LDL) cholesterol was calculated by 
the modified Friedewald equation to be consistent among all STEPS  surveys46.
Definition of terms. Known diabetes was defined as a positive response to either of the two following 
questions: (1) “Have you ever been told by a doctor or other health worker that you have diabetes?” and (2) “Are 
you currently taking insulin or oral medication for diabetes prescribed by a doctor or other health worker?”. 
Hypertension goal/optimum level was defined as mean systolic blood pressure (SBP) < 140  mmHg or mean 
diastolic blood pressure (DBP) < 90  mmHg47. Participants who smoked cigarettes daily were considered ’daily 
smokers’. Glycemic control was defined as a goal of FPG < 130 mg/dL in diabetic subjects and an optimum level 
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of FPG < 100 mg/dL in non-diabetic subjects. Goals/optimum levels for non-HDL cholesterol and LDL choles-
terol were defined as non-HDL cholesterol < 130 mg/dl and LDL cholesterol < 100 mg/dl in those with known 
diabetes and non-HDL cholesterol < 160 mg/dl and LDL cholesterol < 130 mg/dL in those without known dia-
betes. Goals/optimum levels for HDL cholesterol were defined as ≥ 50 mg/dl for women and ≥ 40 mg/dl for men 
and for triglycerides were defined as triglyceride < 150 mg/dl in both  genders47,48.
Statistical analysis. Characteristics of the study population were described by mean (SE) values for con-
tinuous variables and frequency (%) for categorical variables after accounting for the survey nature of the data. 
Since about 10% of the data were missed, the multiple imputation method was used for the estimation of missing 
information. Five imputation sets were performed to impute missing information of FPG, TG, total cholesterol, 
BMI, and blood pressure, using sex, area of living, and age as axillary variables. Survey analysis was performed 
in Stata ver. 12 and the results of all STEPS were weighted using "poststratum weights" according to the national 
Iranian census in 2011; "poststrata" was defined based on categories of age (25–44 years, 45–64 years), sex, resi-
dential area (rural, urban) and the provinces; in this way, the results of all STEPS would be comparable.
The trend of prevalence rates and averages of risk factors in diabetic and non-diabetic subjects were examined 
separately using logistic and linear regressions. The interaction between the trend of risk factors and diabetes 
status was evaluated by adding the interaction term of time × diabetes to the models in pooled data from diabetic 
and non-diabetic subjects.
Received: 24 January 2020; Accepted: 25 June 2020
References
 1. Baena-Díez, J. M. et al. Risk of cause-specific death in individuals with diabetes: a competing risks analysis. Diabetes Care 39, 
1987–1995. https ://doi.org/10.2337/dc16-0614 (2016).
 2. U. K. Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications 
in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317, 703–713 (1998).
 3. Pan, A., Wang, Y., Talaei, M. & Hu, F. B. Relation of smoking with total mortality and cardiovascular events among patients 
with diabetes mellitus: a meta-analysis and systematic review. Circulation 132, 1795–1804. https ://doi.org/10.1161/CIRCU LATIO 
NAHA.115.01792 6 (2015).
 4. Betteridge, D. J. Lipid control in patients with diabetes mellitus. Nat. Rev. Cardiol. 8, 278–290. https ://doi.org/10.1038/nrcar 
dio.2011.23 (2011).
 5. Collins, R. et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a ran-
domised placebo-controlled trial. Lancet 361, 2005–2016. https ://doi.org/10.1016/s0140 -6736(03)13636 -7 (2003).
 6. Hansson, L. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal 
results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351, 1755–1762. https ://doi.
org/10.1016/s0140 -6736(98)04311 -6 (1998).
 7. Shepherd, J. et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary 
heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 29, 1220–1226. https ://doi.org/10.2337/dc05-
2465 (2006).
 8. Ali, M. K. et al. Achievement of goals in U.S. diabetes care, 1999–2010. N. Engl. J. Med. 368, 1613–1624. https ://doi.org/10.1056/
NEJMs a1213 829 (2013).
 9. Saydah, S. H., Fradkin, J. & Cowie, C. C. Poor control of risk factors for vascular disease among adults with previously diagnosed 
diabetes. JAMA 291, 335–342. https ://doi.org/10.1001/jama.291.3.335 (2004).
 10. Jahangiri-Noudeh, Y. et al. Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: a Middle 
Eastern cohort study. PLoS ONE 9, e112639. https ://doi.org/10.1371/journ al.pone.01126 39 (2014).
 11. Kheirandish, M. et al. Secular trends in serum lipid levels of a Middle Eastern adult population; 10 years follow up in Tehran lipid 
and glucose study. Lipids Health Dis. 13, 20. https ://doi.org/10.1186/1476-511X-13-20 (2014).
 12. Eslami, A., Lotfaliany, M., Akbarpour, S., Azizi, F. & Hadaegh, F. Trend of cardiovascular risk factors in the older Iranian popula-
tion: 2002–2014. Geriatrics Gerontol. Int. 18, 130–137. https ://doi.org/10.1111/ggi.13154 (2018).
 13. Farzadfar, F. et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health exami-
nation surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 377, 578–586. https ://doi.
org/10.1016/S0140 -6736(10)62038 -7 (2011).
 14. Zhou, B. et al. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement 
studies with 19·1 million participants. Lancet 389, 37–55. https ://doi.org/10.1016/s0140 -6736(16)31919 -5 (2017).
 15. Azizi, F. et al. Metabolic health in the Middle East and north Africa. Lancet Diabetes Endocrinol. https ://doi.org/10.1016/S2213 
-8587(19)30179 -2 (2019).
 16. Sun, X. & Du, T. Trends in cardiovascular risk factors among U.S. men and women with and without diabetes, 1988–2014. BMC 
Public Health 17, 893. https ://doi.org/10.1186/s1288 9-017-4921-4 (2017).
 17. Preis, S. R. et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham 
Heart Study. Circulation 120, 212–220. https ://doi.org/10.1161/circu latio naha.108.84651 9 (2009).
 18. Samaranayaka, S. & Gulliford, M. C. Trends in cardiovascular risk factors among people with diabetes in a population based study, 
Health Survey for England 1994–2009. Primary Care Diabetes 7, 193–198. https ://doi.org/10.1016/j.pcd.2013.04.010 (2013).
 19. Karam, C. et al. Trends in cardiovascular disease risk factor prevalence and estimated 10-year cardiovascular risk scores in a large 
untreated French Urban Population: the CARVAR 92 study. PLoS ONE 10, e0124817. https ://doi.org/10.1371/journ al.pone.01248 
17 (2015).
 20. Hata, J. et al. Secular trends in cardiovascular disease and its risk factors in Japanese: half-century data from the Hisayama Study 
(1961–2009). Circulation 128, 1198–1205. https ://doi.org/10.1161/circu latio naha.113.00242 4 (2013).
 21. Carroll, M. D. et al. Trends in serum lipids and lipoproteins of adults, 1960–2002. JAMA 294, 1773–1781 (2005).
 22. Carroll, M. D., Kit, B. K., Lacher, D. A., Shero, S. T. & Mussolino, M. E. Trends in lipids and lipoproteins in US adults, 1988–2010. 
JAMA 308, 1545–1554 (2012).
 23. Manne-Goehler, J. et al. Health system performance for people with diabetes in 28 low-and middle-income countries: A cross-
sectional study of nationally representative surveys. PLoS Med. 16, e1002751 (2019).
 24. Torabi, P., Zare, F., Shekholeslam, R. & Safavi, S. M. in 12th Nutritional Congress. Tabriz; Iran.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:11724  | https://doi.org/10.1038/s41598-020-68640-9
www.nature.com/scientificreports/
 25. Mohammadifard, N. et al. Improvement of dietary oil consumption following a community trial in a developing country: The role 
of translational research in health promotion. ARYA Atherosclerosis 9, 29–37 (2013).
 26. Jafari, M., Mohammadi, M., Ghazizadeh, H. & Nakhaee, N. Feasibility and outcome of reducing salt in bread: a community trial 
in Southern Iran. Global J. Health Sci. 8, 163. https ://doi.org/10.5539/gjhs.v8n12 p163 (2016).
 27. Esteghamati, A. et al. Physical activity in Iran: results of the third national surveillance of risk factors of non-communicable diseases 
(SuRFNCD-2007). J. Phys. Activity Health 8, 27–35 (2011).
 28. Momenan, A. A., Delshad, M., Mirmiran, P., Ghanbarian, A. & Azizi, F. Leisure time physical activity and its determinants among 
adults in Tehran: Tehran Lipid and Glucose Study. Int. J. Prevent. Med. 2, 243–251 (2011).
 29. Primatesta, P., Falaschetti, E., Gupta, S., Marmot, M. G. & Poulter, N. R. Association between smoking and blood pressure: evidence 
from the health survey for England. Hypertension 37, 187–193. https ://doi.org/10.1161/01.hyp.37.2.187 (2001).
 30. Venkatesan, A., Hemalatha, A., Bobby, Z., Selvaraj, N. & Sathiyapriya, V. Effect of smoking on lipid profile and lipid peroxidation 
in normal subjects. Indian J. Physiol. Pharmacol. 50, 273–278 (2006).
 31. Derakhshan, A. et al. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and 
Glucose Study. PLoS ONE 9, e102563. https ://doi.org/10.1371/journ al.pone.01025 63 (2014).
 32. Mooy, J. M. et al. Prevalence and determinants of glucose intolerance in a Dutch caucasian population. The Hoorn Study. Diabetes 
Care 18, 1270–1273. https ://doi.org/10.2337/diaca re.18.9.1270 (1995).
 33. Wilson, P. W., Anderson, K. M., Harris, T., Kannel, W. B. & Castelli, W. P. Determinants of change in total cholesterol and HDL-C 
with age: the Framingham Study. J. Gerontol. 49, M252-257. https ://doi.org/10.1093/geron j/49.6.m252 (1994).
 34. Azizi, F. et al. Determinants of serum HDL-C level in a Tehran urban population: the Tehran Lipid and Glucose Study. Nutr. Metab. 
Cardiovasc. Dis. NMCD 12, 80–89 (2002).
 35. Farahmand, M., Tehrani, F. R., Amiri, P. & Azizi, F. Barriers to healthy nutrition: perceptions and experiences of Iranian women. 
BMC Public Health 12, 1064. https ://doi.org/10.1186/1471-2458-12-1064 (2012).
 36. Enjezab, B., Farajzadegan, Z., Taleghani, F. & Aflatoonian, A. Internal motivations and barriers effective on the healthy lifestyle of 
middle-aged women: A qualitative approach. Iran. J. Nurs. Midwifery Res. 17, 390–398 (2012).
 37. Kelishadi, R. et al. Barriers to physical activity in a population-based sample of children and adolescents in Isfahan, Iran. Int. J. 
Prevent. Med. 1, 131–137 (2010).
 38. Farahmand, M. et al. What are the main barriers to healthy eating among families? A qualitative exploration of perceptions and 
experiences of Tehranian men. Appetite 89, 291–297. https ://doi.org/10.1016/j.appet .2015.02.025 (2015).
 39. Harati, H. et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am. J. Prevent. 
Med. 38, 628–636 e621. https ://doi.org/10.1016/j.amepr e.2010.03.003 (2010).
 40. Sarrafzadegan, N. et al. Do lifestyle interventions work in developing countries? Findings from the Isfahan Healthy Heart Program 
in the Islamic Republic of Iran. Bull. World Health Organ. 87, 39–50. https ://doi.org/10.2471/blt.07.04984 1 (2009).
 41. Noshad, S., Afarideh, M., Heidari, B., Mechanick, J. I. & Esteghamati, A. Diabetes care in Iran: where we stand and where we are 
headed. Ann. Global Health 81, 839–850. https ://doi.org/10.1016/j.aogh.2015.10.003 (2015).
 42. Shakibazadeh, E. et al. Patients’ perspectives on factors that influence diabetes self-care. Iran. J. Public Health 40, 146–158 (2011).
 43. Shakibazadeh, E., Bartholomew, L. K., Rashidian, A. & Larijani, B. Persian Diabetes Self-Management Education (PDSME) pro-
gram: evaluation of effectiveness in Iran. Health Promot. Int. 31, 623–634. https ://doi.org/10.1093/heapr o/dav00 6 (2016).
 44. Niroomand, M. et al. Diabetes knowledge, attitude and practice (KAP) study among Iranian in-patients with type-2 diabetes: a 
cross-sectional study. Diabetes Metab. Syndr 10, S114-119. https ://doi.org/10.1016/j.dsx.2015.10.006 (2016).
 45. World Health Organization. NCDs | STEPwise approach to surveillance (STEPS), <https ://www.who.int/ncds/surve illan ce/steps /
en/> (2019).
 46. Chen, Y. et al. A modified formula for calculating low-density lipoprotein cholesterol values. Lipids Health Dis. 9, 52. https ://doi.
org/10.1186/1476-511X-9-52 (2010).
 47. American Diabetes, A. Standards of medical care in diabetes-2017 abridged for primary care providers. Clin. Diabetes 35, 5–26. 
https ://doi.org/10.2337/cd16-0067 (2017).
 48. Association, A. D. 6. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care 42, S61–S70 (2019).
Acknowledgements
We appreciate NCD office at the Ministry of Health and NCD Research Center, Tehran University of Medical 
Sciences for preparing the STEPS data.
Author contributions
H.M., M.L. and D.K. carried out the initial analysis and interpretation of data and drafted the manuscript. D.K. 
and F.H. supervised the study and approved the contents of the manuscript. A.O. and M.Y. coordinated and 
supervised the STEPS surveys and F.F. and F.A. critically reviewed the manuscript.
competing interests 
The authors declare no competing interests.
Additional information
Supplementary information  is available for this paper at https ://doi.org/10.1038/s4159 8-020-68640 -9.
Correspondence and requests for materials should be addressed to D.K.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific RepoRtS |        (2020) 10:11724  | https://doi.org/10.1038/s41598-020-68640-9
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this license, visit http://creat iveco mmons .org/licen ses/by/4.0/.
© The Author(s) 2020
